Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
.webp)
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Ojjaara (momelotinib) is an oral JAK1/JAK2 and ACVR1 inhibitor developed specifically to address myelofibrosis in patients with anemia, a common and challenging complication that limits the use of other JAK inhibitors.
Ojjaara is FDA-approved for adults with intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythemia), who have anemia.
By inhibiting JAK1, JAK2, and ACVR1, momelotinib reduces the abnormal signaling that drives myelofibrosis symptoms, splenomegaly, and constitutional symptoms, while its ACVR1 inhibition helps improve anemia by reducing hepcidin levels.
The recommended dose is 200 mg orally once daily, with or without food. For patients with severe hepatic impairment (Child-Pugh Class C), the starting dose is reduced to 150 mg once daily. Tablets should be swallowed whole and not cut, crushed, or chewed, as determined by the treating hematologist-oncologist.
Ojjaara requires monitoring for several important safety considerations.
Monitor complete blood counts regularly, especially during the first months of treatment.
Serious and fatal bacterial and viral infections, including reactivation of hepatitis B, have occurred. Do not initiate Ojjaara in patients with an active infection. Monitor closely for signs of infection throughout treatment.
Transaminase elevations and, rarely, clinically apparent liver injury have occurred. Monitor liver function periodically.
Screen for hepatitis B before starting treatment in patients at risk.
Ojjaara can cause fetal harm. Advise effective contraception during treatment and for a defined period after the final dose.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Ojjaara (momelotinib) received FDA approval in 2023 and is manufactured by GlaxoSmithKline, addressing an unmet need for myelofibrosis patients with anemia.
Import of Ojjaara through a Named Patient Program requires a valid prescription from the treating hematologist-oncologist, confirmation of myelofibrosis diagnosis and anemia status, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Ojjaara directly from GlaxoSmithKline's authorized supply chain to ensure product authenticity and regulatory compliance.
Ojjaara is sourced through verified, GDP-compliant channels from GlaxoSmithKline's authorized supply chain to ensure authenticity and quality.
Ojjaara tablets should be stored at 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F), in the original bottle with desiccant.
Once sourced, Ojjaara is packed and transported under appropriate temperature-controlled conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Ojjaara through NPP's regulated import pathway, with hematology-oncology specialists in major cities supporting the treatment process.
Leading hematology-oncology centers in Mumbai support myelofibrosis diagnosis and treatment coordination for Ojjaara access.
Delhi's major cancer hospitals assist patients with diagnostic confirmation and prescription support for Ojjaara.
Bangalore's oncology network offers access to myelofibrosis treatment planning for eligible patients.
Chennai-based specialists coordinate Ojjaara access alongside comprehensive myelofibrosis care.
Hyderabad's cancer care institutions support patients pursuing Ojjaara therapy.
Kolkata's oncology centers help coordinate documentation and treatment access for Ojjaara.
Pune-based hematologists assist with diagnosis confirmation and Ojjaara treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Ojjaara.
Kochi's oncology units assist patients with the documentation needed for Ojjaara access.
Chandigarh's cancer care centers support Ojjaara treatment coordination for patients from North India.
Jaipur's oncology specialists help patients navigate the Ojjaara access process.
Lucknow-based cancer centers assist patients pursuing Ojjaara therapy.
Bhubaneswar's oncology institutions support access to Ojjaara for eligible patients.
Guwahati's specialists help coordinate Ojjaara access for patients across the Northeast.
Patients in other cities across India can also access Ojjaara through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 09 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 09 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
